YM BIOSCIENCES PRESENTS RESULTS OF NORELIN STUDY

A A

YM BioSciences presented positive clinical trial results for its anti-GnRH prostate cancer vaccine, Norelin, at the "Cancer Vaccines/Adjuvants/Delivery for the Next Decade" conference in Lisbon, Portugal, which ran from September 5-7.

Norelin is a biological approach to the management of hormone levels in sex-hormone driven cancers and is initially targeting early stage, hormone-sensitive prostate cancer (HSPC). The drug is a fusion protein that combines a proprietary protein sequence in a potent adjuvant formulation. The formulation could represent a well-tolerated and long-lasting control of testosterone and PSA in hormone-dependent patients with prostate cancer thereby affording treatment to a larger population of HSPC patients.